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crease the dose/frequency of octreotide-LAR as 2nd-line therapy in patients with
uncontrolled symptomsup to 60mg every 4weeks or up to 40mg every 3 or 4weeks
for refractory carcinoid syndrome; and 3) as 3rd-line therapy, antiangiogenic ther-
apy may be active in patients with carcinoid tumors. CONCLUSIONS: Treatment
consensus obtained in this study is concordant with NCCN recommendations. The
Delphi process, however, permittedmore detailedmedical treatment guidelines in
a range of key areas in midgut NETs.
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OBJECTIVES: Gastrointestinal neuroendocrine tumors (NETs) are rare and current
treatment guidelines lack specificity in some clinical areas. We present a panel
consensus on medical treatment of well-differentiated (grade 1-2 tumors) unre-
sectable non-pancreatic non-midgut NETs. METHODS: NET treatment appropri-
ateness ratings were collected using the RAND/UCLA Delphi process. We recruited
physician experts (criteria: specialty, geography, practice), reviewed NET treat-
ment literature, and collected 2 rounds of ratings (before and after a face-to-face
meeting) from the experts. Experts and the moderator were blinded to the funding
source. Patient scenarios (rated on a 1-9 scale indicating appropriateness of various
interventions for a given scenario) were labeled as appropriate, inappropriate, or
uncertain. Scenarios with 2 ratings from 1-3 and 2 from 7-9 range were consid-
ered to have disagreement and were not assigned an appropriateness rating.
RESULTS: Ten panelists had amean age of 50.4 years. Specialties representedwere
medical and surgical oncology, interventional radiology, and gastroenterology, and
all practices were affiliated with academic institutions. Panelists had practiced
between 6-33 years. Among 202 non-midgut rated scenarios, disagreement de-
creased from 16.2% (32 scenarios) before the meeting to 3% (6) after. In the 2nd
round, 42.1% (85 scenarios) were rated inappropriate, 34.2% (69) were uncertain,
and 20.8% (42) were appropriate. Consensus statements from the scenarios in-
clude: 1) observation is appropriate in patients with no symptoms and low-volume
radiographically-stable disease; 2) somatostatin analogs may be appropriate in
patients with secretory symptoms; and 3) everolimus or interferon- can be con-
sidered in patients who progressed radiographically or symptomatically on soma-
tostatin analogs. CONCLUSIONS: We obtained appropriateness ratings of variety
medical therapies in NETs from expert physicians. The Delphi process enabled
participants to systematically quantify their assessment of the literature in a valid
and reliable way while improving overall panel consensus on the appropriateness
of medical therapies in non-midgut NETs.
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OBJECTIVES: Tobacco use following cancer diagnosis is a serious concern for neg-
ative health outcomes. Despite ill-effects of tobacco among cancer patients and
negative implications for treatment, many patients continue to use tobacco. On-
cologists have a pivotal role in promoting tobacco cessation throughout treatment.
This study assessed knowledge, readiness, and willingness to conduct and pro-
mote tobacco cessation counseling among a national sample of currently licensed
practicing US Oncology providers. METHODS: A brief survey was administered in
July 2011 via e-mail (N3006) and US postal mail (N1000). Samples were obtained
fromSK&A Information Services, Inc., which used verified addresses and broadcast
e-mail surveyswith one follow-up. Response rateswere 0.6% for e-mail (N19) and
9.6% for postal mail (N96), with a 2.9% overall response rate (N115). RESULTS:
Results showed a majority of oncologists do the following often/almost always
with patients: ask about tobacco use (96.6%); document tobacco use (93.1%); discuss
tobacco use as a cancer risk factor (87.9%); counsel patients on quitting (72.8%); and
assess readiness to quit (68.7%). Findings, however, also reported a majority of
oncologists do the following never/rarely with patients: provide information about
secondhand tobacco smoke (53.5%); provide information on quitlines (59.7%); pro-
vide brochures and self-help guides (64.3%); and follow the 5A’s model for tobacco
treatment (68.6%). On a scale of 0-10, providers indicated they were generally com-
fortable providing cessation counseling [mean7.0; SD2.4]; however, providers
were lesswilling to participate in a tobacco cessation training program for assisting
patients with quitting [mean5.2; SD3.4]. CONCLUSIONS: Findings suggest on-
cology providers are asking, documenting use, and counseling patients who con-
tinue to use tobacco during treatment. Education targeting providers can increase
knowledge and practices related to the 5A’s treatment model, promoting quitline
and self-help information for patients. Effective strategies increasing providerwill-
ingness to attend tobacco treatment training sessions should also be encouraged.
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OBJECTIVES: The main objective was to determine the chemotherapy treatment
and outcome.METHODS:Datawas collected from1 June 2008 till 31 December 2008
in Hospital Kuala Lumpur (HKL) using web-based application. Survival data would
be obtained via linkage with Registration Department after four years. Data anal-
ysis was with STATA statistical software. RESULTS: The total number of patients
was 1192.There were 56% females and the most common age group was 50-59
years. The major ethnic groups were Malay (46.5%), Chinese ( 37.3%) and Indians (
13.8%). Most patients at the oncology clinic at HKL have good performance status
with ECOG 0-1 (61.5%). The most prevalent cancers were breast cancer (24.5%),
colorectal cancer( 17.4%), bronchus and lung cancer 8.6%, cervical cancer 6.5% and
nasopharyngeal cancer (NPC) 6.2%. Most solid tumours were treated by multimo-
dality. 48.8% received 2 or more modalities . There were 547 patients (45.9%) that
received radiotherapy and 32.2% that received chemotherapy. 384 patients were
given cytotoxic chemotherapy .Most patients (84,1%) received just one regime. The
most common regime was a combination of Fluorouracil, Epirubicin and Cyclo-
phosphamide ie FEC (16.4%.) The most often used cytotoxic drugs used were Fluo-
rouracil (26.3%), Cisplatin (15%) followed by Cyclophosphamide (9.9%), Epirubcin
(7.3%), Capecitabine ( 6.4%), Docetaxel (4.2%), Gemcitabine (3.7%). The most often
used route of administration was intravenous ( 92.6%) mostly infusion as opposed
to bolus. Capecitabine was the cytotoxic dug that was the most widely used in the
oral form.CONCLUSIONS:This is only sub-study of a long term research that began
in 2008 in HKL.. Patterns in chemotherapy usage would change as new drugs
emerged in the Formulary. The database would be sustained as a platform for
future researches and for survival analysis. (283 words).
PCN120
THE IMPACT OF UNIVERSAL HEALTH INSURANCE COVERAGE ON USE OF
MEDICINES FOR NON-COMMUNICABLE DISEASES IN THAILAND
Garabedian LF1, Ross-Degnan D1, Stephens P2, Ratanawijitrasin S3, Wagner A1
1Harvard Medical School, Boston, MA, USA, 2IMS Health Consulting Group, London, UK,
3Mahidol University, Salaya, NakornPathom, Thailand
OBJECTIVES: In 2001, Thailand implemented the 30 Baht Scheme, a public insur-
ance scheme that covers the poor and uninsured and pays providers through a
capitated payment scheme. Our objective is to evaluate the impact of the 30 Baht
Scheme on use of medicines in Thailand for three non-communicable diseases:
cancer, cardiovascular disease, and diabetes. METHODS: We used an interrupted
time series design to measure the impact of the 30 Baht Scheme on total pharma-
ceutical market volume and market share. We used IMS Health data on quarterly
purchases of medicines from hospital and retail pharmacies from 1998 to 2006.
RESULTS: The 30 Baht Schemewas associatedwith long-term increases in hospital
sector sales of medicines for conditions that can be adequately treated in outpa-
tient and primary care settings (e.g., diabetes, high cholesterol and high blood
pressure). The policy was associatedwith no change in sales ofmedicines formore
life-threatening diseases, which are more appropriately treated in secondary or
tertiary settings (e.g., myocardial infarction, stroke and cancer). The majority of
sales were for essential medicines, yet there were also post-policy increases for
non-essential medicines. Immediately following the reform, there was a signifi-
cant shift in hospital sector market share by licensing status for most classes of
medicines. We observed large increases in government-produced products, pri-
marily at the expense of branded generics.CONCLUSIONS:Our results suggest that
expanding health insurance coverage with a medicines benefit to the entire Thai
population increased the volume of medicine sales in primary care hospitals. Our
study, however, also suggests that implementation of the 30 Baht Scheme may
have been associated with possibly undesirable effects: increased use of non-es-
sential medicines and decreased use of less expensive generics and medicines in
secondary and tertiary settings. Thorough evaluation of desired and undesired
effects of universal health insurance programs are urgently needed.
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OBJECTIVES: To compare the demographic, clinical and treatment characteristics
of post-menopausal women with advanced ER/HER2- breast cancer (BC) treated
with aromatase inhibitors (AI) who experienced 0 or 1 AI failure (AIF).METHODS:
Women  55 years old, newly diagnosed with metastatic ER/HER2- BC (index)
were identified from the 2006-2010 Thomson Reuters MarketScan databases. Patients
in the 6-month pre- or variable post-index periods treated with endocrine (ET:
tamoxifen, fulvestrant) or AI (anastrozole, letrozole, or exemestane) therapy (ER)
and not with trastuzumab or lapatinib (HER2-), with no pre-index diagnosis of
primary cancer other than BC, and post-index treatmentwith 1 AI were retained.
AIFwas defined post-index as a switch to an alternative AI, ET, or chemotherapy, or
AI discontinuation with no further BC treatment. RESULTS: Among 4274 ER/
HER2- BC patients studied, 61% had 1 AIF (80% had 1 and 20% had 2AIFs). There
was no difference in pre-index AI use (54.4% no AIF, 51.8% AIF; p0.093). At index,
AIF patientsweremore likely to beMedicare-eligible (57% vs. 51%)with liver (7% vs.
4%), lung (10% vs. 8%), bone (56% vs. 48%), and brain (7% vs. 5%) metastases, all
p0.03. Mean follow-up days was shorter for AIF patients (486 vs. 522, p0.006).
First line AI and ET treatments were respectively 95% and 5% for AIF and 97% and
3% for no AIF patients. The most common first line therapy was anastrazole (49%
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